Dr. Ali Kasraeian from Kasraeian Urology is the first in our area to utilize a new minimally invasive treatment, called Focal Therapy, that precisely targets and destroys prostate cancer tumors.

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

In the absence of a trial, a matched analysis compared cancer control after salvage focal therapy vs radical prostatectomy (RP) for radiorecurrent prostate cancer.

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.